NCT02729298 2023-11-14
First-in-human Study of Oral TP-0903 (a Novel Inhibitor of AXL Kinase) in Patients With Advanced Solid Tumors
Sumitomo Pharma America, Inc.
Phase 1 Completed
Sumitomo Pharma America, Inc.
Ohio State University Comprehensive Cancer Center